Astria Therapeutics (NASDAQ:ATXS) Announces Earnings Results, Beats Expectations By $0.01 EPS

Astria Therapeutics (NASDAQ:ATXS) posted its quarterly earnings results on Tuesday. The biotechnology company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.01, Zacks reports.

Astria Therapeutics Price Performance

Shares of Astria Therapeutics stock opened at $7.14 on Thursday. Astria Therapeutics has a 1-year low of $5.73 and a 1-year high of $16.90. The company has a market capitalization of $402.94 million, a PE ratio of -3.42 and a beta of 0.69. The business has a 50-day moving average of $7.23 and a 200-day moving average of $9.59.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on ATXS shares. Citizens Jmp raised shares of Astria Therapeutics to a “strong-buy” rating in a research report on Friday, January 31st. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of Astria Therapeutics in a research report on Tuesday. Wedbush reissued an “outperform” rating and issued a $28.00 price objective (up from $27.00) on shares of Astria Therapeutics in a research report on Wednesday. Oppenheimer boosted their price objective on Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research note on Thursday, November 14th. Finally, JMP Securities began coverage on Astria Therapeutics in a research note on Friday, January 31st. They issued an “outperform” rating and a $26.00 target price for the company. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $26.67.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.